Details the biology and immunophysiology of SARS-CoV-2 and highlights the global vulnerability of the world population to it. Discusses the diagnostics, vaccine development, and therapeutic management covering zoonotic origin, organization, and transmission of SARS-CoV-2, lifestyle and immunophysiology of the virus, and more.
Details the biology and immunophysiology of SARS-CoV-2 and highlights the global vulnerability of the world population to it. Discusses the diagnostics, vaccine development, and therapeutic management covering zoonotic origin, organization, and transmission of SARS-CoV-2, lifestyle and immunophysiology of the virus, and more.
Vivek P. Chavda, MPharm, is currently working as an Assistant Professor in the Department of Pharmaceutics and Pharmaceutical Technology at the L. M. College of Pharmacy, Ahmedabad, Gujarat, India. Before joining academia, he served in the biologics industry for almost eight years in research and development with two successful regulatory filings at Lupin Biotech (Pune) and Dr. Reddy's Laboratory (Hyderabad). He has more than 150 national and international publications, nearly 20 book chapters, several books, one patent in progress as well as numerous newsletter articles to his credit. His research interests include development of biologics processes and formulations, medical device development, nano-diagnostics, long-acting parenteral formulations, and nano-vaccines. He earned his BPharm and MPharm degrees (with gold medals) at Gujarat Technological University, Gujarat, India. Vladimir N. Uversky, PhD, DSc, FRSB, FRSC, is a full Professor in the Department of Molecular Biology, University of South Florida, Tampa, Florida, USA. Dr. Uversky works on various aspects of protein intrinsic disorder phenomenon and on analysis of protein folding and misfolding. He has authored over 1150 scientific publications. According to the Thomson Reuters' Web of Science, his work was cited over 66,000 times, and he has an h-index of 126. Dr. Uversky has been included in the prestigious Clarivate List of Highly Cited Researchers(TM) every year from 2014 to 2020. In 2021, he was elected as a Fellow of the Royal Society of Biology and a Fellow of the Royal Society of Chemistry. Over the years, he has delivered more than 240 invited talks at various national and international conferences and invited seminars in various universities and research institutions around the globe. Dr. Uversky has collaborated with more than 12,500 colleagues from more than 2,750 research organizations in 89 countries/territories. He is an editor of a number of scientific journals and has edited several books and book series on protein structure, function, folding, and misfolding. He obtained his PhD in Biophysics from the Moscow Institute of Physics and Technology and DSc in Biophysics from the Institute of Experimental and Theoretical Biophysics, Russian Academy of Sciences.
Inhaltsangabe
Foreword by Elrashdy M. Redwan 1. Zoonotic Origin, Genomic Organization, Transmission, and Mutation of SARS CoV 2 2. SARS CoV 2 Life Cycle and Immuno Pathophysiology 3. Conventional and Novel Diagnostics for the Detection of SARS CoV 2 Variants 4. Biosensors: An Advanced and Sensitive Analytical Technique for the Early Detection of SARS CoV 2 Variants 5. Global Impact of Delta and Omicron Variants of SARS CoV 2 6. Drug Repurposing for Covid 19 and Fast Track New Drug Discovery for Emerging SARS CoV 2 Variants 7. Characterization of SARS CoV 2 Variants Using Respiratory Organoids and Organs on a Chip (OOACs) 8. Fast Track Vaccine Development for Covid 19 and Impact of Emerging Variants 9. Nasal Vaccine for the Control of Emerging Variants of SARS CoV 2 10. Role of Nucleic Acid Vaccines for the Management of Emerging Variants of SARS CoV 2 11. Role of Monoclonal Antibodies for the Management of Immersing Variant of SARS CoV 2 12. Dietary Supplements and Nutraceuticals Against Variants of SARS CoV 2 13. Herbal Remedies for Covid 19 Management 14. Covid 19 and Post Covid 19 Associated Complications and Their Management 15. SARS CoV 2 Variants and Global Vulnerability: Diagnostic, Vaccines, and Therapeutic Management 16. Socio Economic and Environmental Impact of SARS CoV 2 Variants 17. Nanotechnology Based Interventions for Covid 19 Management 18. SARS CoV 2 Variants and Covid 19 Pandemic: Future Perspectives
Foreword by Elrashdy M. Redwan 1. Zoonotic Origin, Genomic Organization, Transmission, and Mutation of SARS CoV 2 2. SARS CoV 2 Life Cycle and Immuno Pathophysiology 3. Conventional and Novel Diagnostics for the Detection of SARS CoV 2 Variants 4. Biosensors: An Advanced and Sensitive Analytical Technique for the Early Detection of SARS CoV 2 Variants 5. Global Impact of Delta and Omicron Variants of SARS CoV 2 6. Drug Repurposing for Covid 19 and Fast Track New Drug Discovery for Emerging SARS CoV 2 Variants 7. Characterization of SARS CoV 2 Variants Using Respiratory Organoids and Organs on a Chip (OOACs) 8. Fast Track Vaccine Development for Covid 19 and Impact of Emerging Variants 9. Nasal Vaccine for the Control of Emerging Variants of SARS CoV 2 10. Role of Nucleic Acid Vaccines for the Management of Emerging Variants of SARS CoV 2 11. Role of Monoclonal Antibodies for the Management of Immersing Variant of SARS CoV 2 12. Dietary Supplements and Nutraceuticals Against Variants of SARS CoV 2 13. Herbal Remedies for Covid 19 Management 14. Covid 19 and Post Covid 19 Associated Complications and Their Management 15. SARS CoV 2 Variants and Global Vulnerability: Diagnostic, Vaccines, and Therapeutic Management 16. Socio Economic and Environmental Impact of SARS CoV 2 Variants 17. Nanotechnology Based Interventions for Covid 19 Management 18. SARS CoV 2 Variants and Covid 19 Pandemic: Future Perspectives
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
